Pulmotect, Inc. They have developed an innovative and pathogen agnostic approach to prevent and treat respiratory complications by harnessing the power of the innate immune system. Their lead program, PUL-042, is a groundbreaking inhaled therapy that activates the innate immunity of the lungs.

With a focus on enhancing outcomes in immunosuppressed oncology patients and other high-risk populations, Pulmotect is committed to improving respiratory health and reducing the risk of complications from respiratory infections. The development of their strategy is backed by strong pre-clinical data and positive results from Phase 1 and Phase 2 studies with PUL-042. Pulmotect's dedication to innovation and their emphasis on leveraging the innate immune system make them a brand to watch in the field of respiratory health.

For more information about their pipeline and their groundbreaking products, visit their website